Scarica l'app Stockscreener
4.56
5.30%
-0.255
Dopo l'orario di chiusura:
4.58
0.02
+0.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARDX Giù?
Forum
Previsione
Precedente Chiudi:
$4.815
Aprire:
$4.75
Volume 24 ore:
4.42M
Relative Volume:
1.04
Capitalizzazione di mercato:
$1.09B
Reddito:
$251.85M
Utile/perdita netta:
$-72.58M
Rapporto P/E:
-14.55
EPS:
-0.3134
Flusso di cassa netto:
$-63.80M
1 W Prestazione:
-0.22%
1M Prestazione:
-11.11%
6M Prestazione:
-22.45%
1 anno Prestazione:
-29.63%
Intervallo 1D:
$4.54
$4.81
Intervallo di 1 settimana:
$4.505
$4.83
Portata 52W:
$4.02
$9.33
Ardelyx Inc Stock (ARDX) Company Profile
Nome
Ardelyx Inc
Settore
Industria
Telefono
510-745-7047
Indirizzo
34175 ARDENWOOD BLVD., FREMONT, CA
Confronta ARDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
4.56 | 1.09B | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Ripresa | Ladenburg Thalmann | Buy |
| 2025-03-04 | Iniziato | BTIG Research | Buy |
| 2024-11-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-18 | Iniziato | Raymond James | Strong Buy |
| 2023-09-07 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-25 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-11-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | Downgrade | Jefferies | Buy → Hold |
| 2021-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-23 | Iniziato | Wedbush | Outperform |
| 2021-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-20 | Ripresa | Citigroup | Buy |
| 2020-02-18 | Ripresa | Jefferies | Buy |
| 2020-02-12 | Iniziato | Citigroup | Buy |
| 2020-02-10 | Iniziato | Cowen | Outperform |
| 2019-04-08 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-24 | Iniziato | Jefferies | Buy |
| 2018-03-19 | Ripresa | Leerink Partners | Outperform |
| 2017-11-29 | Reiterato | Citigroup | Buy |
| 2017-11-22 | Reiterato | Ladenburg Thalmann | Buy |
| 2017-10-17 | Ripresa | Leerink Partners | Outperform |
| 2016-03-31 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-03-09 | Iniziato | Cantor Fitzgerald | Buy |
| 2016-03-03 | Iniziato | Citigroup | Buy |
Mostra tutto
Ardelyx Inc Borsa (ARDX) Ultime notizie
Press Release Distribution & PR Platform - ACCESS Newswire
Lobbying Update: $620,000 of ARDELYX INC. lobbying was just disclosed - Nasdaq
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025 - The Manila Times
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025 | ARDX Stock News - GuruFocus
Ardelyx, Inc. Schedules Conference Call to Discuss Q1 2025 Financial Results and Business Update - Nasdaq
Is Ardelyx Inc. (NASDAQ:ARDX) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
April 2025's Top Penny Stocks To Watch - Yahoo Finance
13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey
Stride Announces Date for Third Quarter Fiscal Year 2025 Earnings Call - The Globe and Mail
Ardelyx reveals new findings on CKD treatment XPHOZAH at NKF event - Investing.com Canada
Ardelyx reveals new findings on CKD treatment XPHOZAH at NKF event By Investing.com - Investing.com South Africa
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings - The Manila Times
Ontario Teachers' Appoints Terry Hickey as Chief Technology Officer - The Globe and Mail
Class Action Filed Against Ardelyx, Inc. (ARDX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
ARDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Ardelyx CEO Michael Raab sells $191k in stock - Investing.com
Ardelyx CEO Michael Raab sells $191k in stock By Investing.com - Investing.com UK
Ardelyx stock hits 52-week low at $4.29 amid challenges By Investing.com - Investing.com South Africa
Ardelyx stock hits 52-week low at $4.29 amid challenges - Investing.com Australia
How To Trade (ARDX) - news.stocktradersdaily.com
Levi's (LEVI) Reports Q1: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 15, 2024 in Ardelyx, Inc. LawsuitARDX - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 15, 2024 in Ardelyx LawsuitARDX - ACCESS Newswire
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings - The Manila Times
First-in-Class Kidney Disease Drug XPHOZAH Reveals Breakthrough Clinical Results - Stock Titan
Commit To Purchase Ardelyx At $4, Earn 20.5% Annualized Using Options - Nasdaq
Institutional owners may take dramatic actions as Ardelyx, Inc.'s (NASDAQ:ARDX) recent 6.4% drop adds to one-year losses - simplywall.st
How to Take Advantage of moves in (ARDX) - news.stocktradersdaily.com
Shareholders that lost money on Ardelyx, Inc.(ARDX) should contact Levi & Korsinsky about pending Class ActionARDX - ACCESS Newswire
Ardelyx Requests to Dismiss Class Action Filed by Investors - TradingView
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - Marketscreener.com
ARDELYX INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Trading (ARDX) With Integrated Risk Controls - news.stocktradersdaily.com
Ardelyx honors inaugural Derek Forfang award winners By Investing.com - Investing.com Australia
Ardelyx at Barclays Conference: Pipeline Expansion and Revenue Growth - Investing.com
Ardelyx at Barclays Conference: Pipeline Expansion and Revenue Growth By Investing.com - Investing.com UK
Ardelyx honors inaugural Derek Forfang award winners - Investing.com India
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award - The Manila Times
Five Champions of Kidney Disease Advocacy Receive Groundbreaking Ardelyx Recognition - StockTitan
Insider Buying: David Mott Acquires Shares of Ardelyx Inc (ARDX) - GuruFocus.com
Piper Sandler maintains $8 target on Ardelyx shares amid uncertainty By Investing.com - Investing.com South Africa
Piper Sandler maintains $8 target on Ardelyx shares amid uncertainty - Investing.com India
8,020 Shares in Ardelyx, Inc. (NASDAQ:ARDX) Bought by SBI Securities Co. Ltd. - Defense World
Ardelyx at Leerink Global Healthcare Conference: Navigating Challenges and Opportunities By Investing.com - Investing.com South Africa
Ardelyx at Leerink Global Healthcare Conference: Navigating Challenges and Opportunities - Investing.com India
Ardelyx Inc Azioni (ARDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
4.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):